Abstract:Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.

Cell Therapy and 3D Regenerative Tissue to Remodel Heart Failure

The Challenges Of Stem Cell Therapy In Myocardial Infarction And Heart Failure And The Potential Strategies To Improve The Outcomes

Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Biomaterials‐based Cell Therapy for Myocardial Tissue Regeneration

Treatment of Heart Failure after Myocardial Infarction with Bone Marrow-derived Mesenchymal Stem Cells

Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?

Advancing cardiac regeneration through 3D bioprinting: methods, applications, and future directions

Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

3D bioprinting in cardiac tissue engineering

Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction

Advances of Stem Cell Therapy to Treat Heart Failure

3D Bioprinted Cardiac Tissues and Devices for Tissue Maturation

Advances in three-dimensional bioprinted stem cell-based tissue engineering for cardiovascular regeneration

Regenerative Therapy for Cardiomyopathies

3D Bioprinting Technology – One Step Closer Towards Cardiac Tissue Regeneration

Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering.

Stem Cells for Tissue Engineering of Myocardial Constructs

Strategies for Constructing Pluripotent Stem Cell- and Progenitor Cell-Derived Three-Dimensional Cardiac Micro-Tissues.

Engineering Three-Dimensional Cardiac Microtissues for Potential Drug Screening Applications.